CIC
CUE icon

Cornercap Investment Counsel’s Cue Biopharma CUE Stock Holding History

Cornercap Investment Counsel’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,930
Closed -$109K – 617
2024
Q1 		$109K Hold
1,930
– – 0.02% 584
2023
Q4 		$153K Hold
1,930
– – 0.03% 548
2023
Q3 		$133K Sell
1,930
-25
-1% -$2.44K 0.02% 524
2023
Q2 		$214K Buy
+1,955
New +$230K 0.04% 502

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Cornercap Investment Counsel's CUE Position: Q2 2024 in Review

Cornercap Investment Counsel sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 1,930 shares — an estimated $109K sold.

Cornercap Investment Counsel first reported a position in CUE in Q2 2023 and held it in 4 quarters. The position peaked at $214K in Q2 2023. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Cornercap Investment Counsel reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 1,930 Cue Biopharma shares in Q2 2024, an estimated $109K.
  • Cornercap Investment Counsel first reported a position in Cue Biopharma in Q2 2023 and held it in 4 quarters.
  • Cornercap Investment Counsel's Cue Biopharma position peaked at $214K in Q2 2023.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Cornercap Investment Counsel's 13F filing for Q2 2024, filed 8 Aug 2024.